Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
In a recent publication Raffi et al. suggest that it may be time to drop efavirenz (Sustiva®) from 1st line HIV treatment recommendations [1]. The authors make the claim that efavirenz was inferior to rilpivirin (Edurant®) and dolutegravir (Tivicay®) in a total of Continue reading Should Efavirenz Remain a Tier 1 ART Drug?
US doctors seem to be very willing to start drugs earlier in disease, while their EU colleagues are slower and more conservative. Recent examples: the ever-wider indication for statins, the disproportionate uptake of drugs for attention-deficit / hyperactivity and opioids Continue reading HIV Therapy Guidance Recommendations Diverge, Show US Bias